Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 sub-study 04C of MK-2870 + enfortumab vedotin with or without pembrolizumab in advanced urothelial carcinoma
MOH_2024-07-25_013485Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sacituzumab tirumotecan, enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Pharmacokinetics. Started Jun 2024; status: active, not recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2024-07-25_013485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-25_013485.